Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01616524 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
NCT01616524 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 880 participants.
The verdict
NCT01616524, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared to 24 weeks of treatment with Pegylated Interferon Alfa-2a plus Ribavirin
Interventions
- DRUG Ribavirin
- BIOLOGICAL Pegylated interferon lambda (pegIFNλ)
- BIOLOGICAL Pegylated interferon alfa-2a (pegIFNα-2a)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01616524
The ClinicalTrials.gov registry entry for NCT01616524 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 880 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01616524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01616524 about?
NCT01616524 is a clinical study titled "Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3". The purpose of this study is to determine if 24 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and 12 weeks of treatment with Pegylated Interferon Lambda plus Ribavirin and Daclatasvir will be safe and effective for treatment of hepatitis C compared to 24 weeks of treatment with ...
What is the current status of trial NCT01616524?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2012-07. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01616524?
The interventions under investigation include: Ribavirin (DRUG), Pegylated interferon lambda (pegIFNλ) (BIOLOGICAL), Pegylated interferon alfa-2a (pegIFNα-2a) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01616524?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.